Italia markets closed

Biogen Inc. (BIIB)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a portafoglio
291,71-1,49 (-0,51%)
Alla chiusura: 4:00PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente293,20
Denaro288,00 x 1100
Lettera292,00 x 800
Min-Max giorno289,06 - 293,47
Intervallo di 52 settimane223,25 - 468,55
Media Volume1.123.836
Beta (5 anni mensile)0,39
Rapporto PE (ttm)23,33
EPS (ttm)12,50
Prossima data utili19 ott 2021 - 25 ott 2021
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1A416,37
  • GlobeNewswire

    Biogen R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multiple Novel Therapies in Neuroscience

    33 early and late-stage clinical programs across modalities and innovative discovery platformsUniquely positioned to lead in Alzheimer’s disease with ADUHELM® (aducanumab-avwa) and industry-leading pipeline including Phase 3 lecanemab Potential to transform standard of care in several areas of high unmet need in depression, ALS, stroke and lupusBiomarkers and digital health to enable early diagnosis and personalized medicineContinued leadership in neuroscience sustained by distinct capabilities

  • GlobeNewswire

    FDA Approves Samsung Bioepis and Biogen’s BYOOVIZ™ (SB11), LUCENTIS® Biosimilar (ranibizumab-nuna)

    BYOOVIZ™ becomes the first ophthalmology biosimilar to gain FDA approval in the United States INCHEON, Korea and CAMBRIDGE, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has approved BYOOVIZ™ (ranibizumab-nuna), a biosimilar referencing LUCENTIS® (ranibizumab)i, for the treatment of neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occ

  • GlobeNewswire

    CHMP Recommends VUMERITY® (diroximel fumarate) for Approval in the European Union as a Treatment for Relapsing-Remitting Multiple Sclerosis

    VUMERITY is a next-generation oral fumarate with a well-characterized efficacy and safety profileData from the Phase 3 EVOLVE-MS-2 study have demonstrated that treatment with VUMERITY results in low discontinuation rates due to its gastrointestinal (GI) tolerability profile Upon approval, VUMERITY will offer a new oral option for MS patients as they consider treatment initiation in the context of the COVID-19 environment CAMBRIDGE, Mass., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: B